Immunotherapy targeting toxic Tau reduces and mitigates cognitive decline, and senescence in a human Tau mouse model
Fadhl Al‐Shaebi, Sudipta Senapati, Alessia Sciortino, Marina Farag, Madison Samples, Rhea Xavier, Rakez Kayed · 2025
Read Immunotherapy targeting toxic Tau reduces and mitigates cognitive decline, and senescence in a human Tau mouse model by Fadhl Al‐Shaebi, Sudipta Senapati, Alessia Sciortino, Marina Farag, Madison Samples, Rhea Xavier, Rakez Kayed (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709545.txt.
Description
Fadhl Al-Shaebi and co-authors test antibody treatment for toxic tau in mice in this 2025 study. In Alzheimer's disease, tau protein builds up in the brain, tangles inside cells, and drives slow loss of thinking. The team used mice carrying the human tau gene and seeded their brains with toxic tau clumps taken from patient brains.
Seven months later, the mice got doses of lab-made antibodies aimed at the toxic form of tau, or a dummy antibody. Treated mice showed lower total tau and less of its harmful marked form in the brain. Signs of inflammation and of cells aging early also fell. Thinking and movement tests were run before the brains were checked. The authors read the results as support for tau-targeting immune therapy in related diseases.
Catalog record
| CREATOR | Fadhl Al‐Shaebi, Sudipta Senapati, Alessia Sciortino, Marina Farag, Madison Samples, Rhea Xavier, Rakez Kayed |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |